Palvella Therapeutics (NASDAQ:PVLA) Given New $105.00 Price Target at Truist Financial

Palvella Therapeutics (NASDAQ:PVLA) had its target price increased by Truist Financial from $80.00 to $105.00 in a research note released on Monday morning,Benzinga reports. They currently have a buy rating on the stock.

A number of other brokerages have also commented on PVLA. Stifel Nicolaus boosted their price target on Palvella Therapeutics from $60.00 to $80.00 and gave the company a “buy” rating in a report on Wednesday, September 24th. Raymond James Financial set a $54.00 target price on Palvella Therapeutics and gave the company an “outperform” rating in a research report on Tuesday, August 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Palvella Therapeutics in a research report on Wednesday, October 8th. Oppenheimer started coverage on shares of Palvella Therapeutics in a report on Tuesday, September 9th. They issued an “outperform” rating and a $85.00 price objective on the stock. Finally, Lifesci Capital started coverage on shares of Palvella Therapeutics in a research report on Monday, August 4th. They issued an “outperform” rating and a $90.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Palvella Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $99.67.

Palvella Therapeutics Stock Up 3.2%

Shares of PVLA stock opened at $80.29 on Monday. The firm has a fifty day moving average of $66.65 and a 200-day moving average of $43.36. Palvella Therapeutics has a 12-month low of $11.17 and a 12-month high of $83.00. The company has a market capitalization of $888.01 million, a price-to-earnings ratio of -21.18 and a beta of -0.05.

Palvella Therapeutics (NASDAQ:PVLA) last issued its quarterly earnings data on Tuesday, November 11th. The company reported ($1.03) EPS for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.18). On average, equities analysts expect that Palvella Therapeutics will post -3.69 EPS for the current year.

Hedge Funds Weigh In On Palvella Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Clio Asset Management LLC bought a new stake in Palvella Therapeutics during the second quarter worth $2,063,000. Woodline Partners LP acquired a new position in shares of Palvella Therapeutics during the 1st quarter worth about $5,435,000. Goldman Sachs Group Inc. bought a new stake in shares of Palvella Therapeutics in the 1st quarter valued at about $533,000. Frazier Life Sciences Management L.P. lifted its stake in Palvella Therapeutics by 5.5% in the 1st quarter. Frazier Life Sciences Management L.P. now owns 690,012 shares of the company’s stock valued at $19,313,000 after purchasing an additional 36,120 shares during the last quarter. Finally, Royce & Associates LP acquired a new stake in Palvella Therapeutics in the 1st quarter valued at about $2,002,000. 40.11% of the stock is owned by institutional investors.

About Palvella Therapeutics

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.